Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma

(2011) Hikmat A Al-Ahmadie et al.   JOURNAL OF PATHOLOGY

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

(2010) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

The Importance of Identifying and Validating Prognostic Factors in Oncology

(2010) Susan Halabi et al.   SEMINARS IN ONCOLOGY

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

(2009) G. K. Philips et al.   ANNALS OF ONCOLOGY

Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium

(2009) Matthew I. Milowsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

(2009) Fauconnet   ONCOLOGY REPORTS

Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

(2008) Christian Jessen et al.   ACTA ONCOLOGICA